RxDoctor Payments Data

Merin Kinikini

Nurse Practitioner · Salt Lake City, UTNPI 1326127895

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (32.1%), speaking fees and consulting fees — rather than concentrated in one kind of arrangement. Fresenius Kabi USA, LLC accounts for 83.3% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2023 at $8,201 and has fallen 59.9% since, to $3,285 in 2025. Among nurse practitioner clinicians in UT with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$18,983in general payments, 2019–2025

Across 85 payments — averaging $223.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Fresenius Kabi USA, LLC$16K
  • Takeda Pharmaceuticals U.S.A., Inc.$2K
  • Eisai Inc.$930
  • AbbVie$196
  • E.r. Squibb & Sons, L.L.C.$130
  • Abbott$88
  • plus $13 from 1 others

What the payments were for

  • Consulting fees$5,46529%
  • Speaking & faculty fees$5,49029%
  • Travel & lodging$6,08632%
  • Food & beverage$1,94110%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$18,983 in reported general payments places this provider in the 95th percentile of 979 nurse practitioner providers in Utah.

See all nurse practitioner providers in Utah

Medicare billing

Part B allowed, 2024
$6,219
Medicare patients
48
Services billed
105

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Lactated RingersRinger's Solution,lactated264$9,262
LoperamideLoperamide Hcl31$2,785
Octreotide Acetate26$2,602
Promethazine Hcl76$2,037
Sodium Chloride0.9 % Sodium Chloride132$1,911
Ondansetron Hcl128$1,780
Pantoprazole Sodium22$530
Magnesium Sulfate133$447
Vitamin D2Ergocalciferol (Vitamin D2)11$445
Diphenhydramine Hcl56$333
Potassium Chloride73$279
Furosemide25$88

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius Kabi USA, LLCSodium Chloride, Magnesium Sulfate$15,813$2,359265 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 979 nurse practitioner providers in Utah.

Other nurse practitioner in Salt Lake City

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →